Actively Recruiting

Phase 4
Age: 19Years - 80Years
All Genders
NCT04755387

Ticagrelor De-escalation Strategy in AMI Patients

Led by Dong-A University · Updated on 2025-10-01

2312

Participants Needed

1

Research Sites

253 weeks

Total Duration

On this page

Sponsors

D

Dong-A University

Lead Sponsor

B

Biotronik SE & Co. KG

Collaborating Sponsor

AI-Summary

What this Trial Is About

DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. The EASTYLE trial will evaluate a hybrid DAPT de-escalation strategy (reduced-dose ticagrelor, followed by aspirin early discontinuation) in AMI patients, compared with a conventional DAPT strategy.

CONDITIONS

Official Title

Ticagrelor De-escalation Strategy in AMI Patients

Who Can Participate

Age: 19Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis with acute myocardial infarction
  • Age 19 years or older
  • Successful PCI with ultrathin bioresorbable polymer sirolimus-eluting stents (Orsiro; Biotronik AG)
  • Provision of informed consent
Not Eligible

You will not qualify if you...

  • Any prior event of hemorrhagic stroke or intracranial hemorrhage
  • Active bleeding or high risk of serious bleeding
  • Bleeding disorders or coagulopathy (e.g., hemoglobin ≤ 10 g/dL, platelet count < 100,000/µL, recent transfusion)
  • Allergy to stent metal, contrast media, or antiplatelet drugs
  • Moderate to severe liver dysfunction (Child-Pugh class B or C)
  • Need for oral anticoagulation therapy
  • Current or potential pregnancy
  • Treatment with strong CYP3A4 inhibitors
  • Life expectancy less than 1 year

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

DongA University Hospital

Busan, South Korea, 602-715

Actively Recruiting

Loading map...

Research Team

M

Moo Hyun Kim, MD, PhD

CONTACT

Y

Young-Hoon Jeong, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here